Maravai Lifesciences Holdings, Inc. (MRVI) Stock Price & Analysis
Maravai Lifesciences Holdings, Inc. (MRVI) fell 4.11% to USD 6.76 as of July 25, 2026 at 02:21 UTC, according to Nexqual real-time market data.
MRVI last closed at USD 7.05; the session ranged USD 6.75–7.13 on volume of 1,872,838 shares. Market capitalization is $2.49B, with a 52-week range of USD 1.99–7.44 (NMS). Source: Nexqual, July 25, 2026 at 02:21 UTC.
Key Statistics (as of July 25, 2026 at 02:21 UTC)
| Price | USD 6.76 |
|---|---|
| Change | ▼ 4.11% (down) |
| Previous Close | USD 7.05 |
| Open | USD 7.09 |
| Day Range | USD 6.75 – 7.13 |
| 52-Week Range | USD 1.99 – 7.44 |
| Volume | 1,872,838 shares |
| Market Cap | $2.49B |
| Exchange | NMS |
Technical Analysis (MRVI)
Nexqual's technical model rates MRVI "STRONG BUY" based on 5 bullish and 0 bearish signals across 125 daily candles, as of July 25, 2026 at 02:21 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 61.97 (neutral) |
| vs SMA50 | Above (USD 5.51) |
| MACD | 0.46 (positive) |
Analyst Ratings (MRVI)
Wall Street analysts rate MRVI "Buy" based on 5 analysts, with a mean price target of USD 5.9 (range USD 5–7), per Nexqual as of July 25, 2026 at 02:21 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 5.9 |
| High Target | USD 7 |
| Low Target | USD 5 |
| Buy / Hold / Sell | 5 / 3 / 0 |
Earnings (MRVI)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD -0.04 |
| Revenue Estimate | $48.68M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.01 vs est -0.05 ▲ beat |
| 2025-12-31 | USD -0.04 vs est -0.07 ▲ beat |
| 2025-09-30 | USD -0.08 vs est -0.08 ▲ beat |
| 2025-06-30 | USD -0.08 vs est -0.07 ▼ miss |
Source: Nexqual, July 25, 2026 at 02:21 UTC.
Financials & Fundamentals (MRVI)
| Total Revenue | $204.73M |
|---|---|
| Revenue Growth (YoY) | +40.50% |
| Gross Margin | +30.12% |
| Operating Margin | +1.09% |
| Profit Margin | -51.07% |
| ROE | -40.98% |
| Debt / Equity | 85.36 |
| Current Ratio | 5.91 |
| Total Cash | $165.92M |
| Total Debt | $315.03M |
| Free Cash Flow | $-11.33M |
Source: Nexqual, July 25, 2026 at 02:21 UTC.
Financial Health Score (MRVI)
Nexqual rates Maravai Lifesciences Holdings, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 02:21 UTC.
| Growth | Critical — Revenue -28% YoY (annual), sharp decline |
|---|---|
| Profitability | Mixed — Gross margin 30%, operating 1% |
| Balance Sheet | Mixed — $166M cash vs $315M debt |
| Cash Flow | Weak — FCF negative: -$11M, burning cash |
| Efficiency | Critical — ROE -41%, ROA -6.6% |
Ownership (MRVI)
| Insider Ownership | +13.80% |
|---|---|
| Institutional Ownership | +88.11% |
| Shares Outstanding | 147.51M |
| Float | 101.17M |
| Short % of Float | +7.09% |
Source: Nexqual, July 25, 2026 at 02:21 UTC.
Leadership (MRVI)
Maravai Lifesciences Holdings, Inc. is led by Bernd Brust (age 58), CEO & Director, per Nexqual as of July 25, 2026 at 02:21 UTC.
| CEO & Director | Bernd Brust (age 58) |
|---|---|
| Chairman of the Board | Robert Andrew Eckert (age 63) |
| EVP & Chief Financial Officer | Rajesh J. Asorpota (age 58) |
| Senior VP & Chief Scientific Officer | Chanfeng Zhao |
| Senior Director of Investor Relations | Debra Hart |
Major Backers & Investors (MRVI)
Notable institutional backers of Maravai Lifesciences Holdings, Inc. include GTCR, LLC, Braidwell LP , 12 West Capital Management Lp, according to Nexqual as of July 25, 2026 at 02:21 UTC.
Active Investors
| Investor | Stake |
|---|---|
| GTCR, LLC | 13.66% |
| Braidwell LP | 6.94% |
| 12 West Capital Management Lp | 4.92% |
| Mackenzie Financial Corporation | 4.28% |
| Renaissance Technologies | 2.89% |
| Tejara Capital Ltd | 2.37% |
| Monaco Asset Management SAM | 2.32% |
| Morgan Stanley | 2.25% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 9.29% |
| Vanguard Group | 7.3% |
Source: Nexqual, July 25, 2026 at 02:21 UTC.
From Maravai Lifesciences Holdings, Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America.
- It operates through two segments: TRILINK and CYGNUS.
- The TRILINK segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, and oligonucleotide therapy, as well as molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA).
- This segment also offers messenger RNA, oligonucleotides, CleanCap capping technology-based oligonucleotide building blocks, and custom enzyme development and manufacturing; and research products for labeling and detecting proteins in cells and tissue samples.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SHC | Sotera Health Company | USD 17.35 | ▲ 0.35% |
| CERT | Certara, Inc. | USD 7.51 | ▲ 9% |
| SEER | Seer, Inc. | USD 1.97 | ▼ 4.83% |
| CCCC | C4 Therapeutics, Inc. | USD 3.4 | ▼ 9.09% |
| BCAB | BioAtla, Inc. | USD 3.37 | ▼ 0.59% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 02:21 UTC. This page is informational and not investment advice.